Skip to main content
HVIVO PLC logo

HVIVO PLC — Investor Relations & Filings

Ticker · HVO ISIN · GB00B9275X97 LEI · 213800VT5KBM7JLIV118 IL Professional, scientific and technical activities
Open in API
Filings indexed 741 across all filing types
Latest filing 2026-05-20 Regulatory Filings
Country GB United Kingdom
Listing IL HVO

About HVIVO PLC

https://hvivo.com/

hVIVO plc is a full-service contract research organization (CRO) and a leading specialist in human challenge trials. The company provides end-to-end clinical development solutions for a global biopharma client base, focusing on infectious and respiratory diseases. Its services span from preclinical consultancy to Phase III clinical trials, including first-in-human studies, biometry, and consulting. hVIVO operates a state-of-the-art quarantine facility in London and provides advanced laboratory services under its hLAB brand. Through subsidiaries such as CRS and Venn Life Sciences, it offers early-phase clinical trial expertise and patient recruitment across multiple clinical sites. The company's integrated approach is designed to accelerate the development of vaccines and therapeutics.

Recent filings

Filing Released Lang Actions
Capital Markets Day
Regulatory Filings Classification · 82% confidence The document is an RNS release announcing an upcoming Capital Markets Day event (investor meeting) on 11 June 2026. It contains event details and speakers but does not include substantive financial statements or the actual presentation materials. It is not a financial report itself, nor a notice of report publication, but rather a regulatory news service announcement. Therefore, it falls under the fallback category of Regulatory Filings (RNS).
2026-05-20 English
Result of AGM
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is an RNS announcement titled “Result of AGM” stating that all resolutions at the Annual General Meeting were duly passed and noting that voting results will be published shortly. This is clearly an announcement of shareholder vote outcomes at an AGM, matching the Declaration of Voting Results & Voting Rights Announcements category.
2026-05-13 English
Holding(s) in Company
Major Shareholding Notification Classification · 95% confidence The document is a TR-1 standard form for notification of major holdings under the UK/EU transparency rules, showing a shareholder (Octopus Investments Limited) crossing a voting rights threshold. This is a major shareholding notification, fitting the MRQ classification.
2026-05-12 English
£6m Influenza HCT contract signed
Regulatory Filings
2026-05-07 English
Director/PDMR Shareholding
Director's Dealing Classification · 98% confidence The document is an RNS announcement dated 24 April 2026 detailing a Non-Executive Director’s sale of 2,017,000 ordinary shares, including transaction details, ISIN, dates, and volumes. This matches the definition of a Director’s Dealing report (insider trades by directors).
2026-04-24 English
HCT contract signed with ILiAD Biotechnologies
Regulatory Filings Classification · 90% confidence The document is a regulatory press release distributed via the London Stock Exchange’s RNS service. It announces a business contract to conduct a pivotal Phase III trial, but is not an earnings report, management discussion, financing notice, or other specific category. It is a general corporate announcement and falls under the fallback Regulatory Filings (RNS) category.
2026-04-22 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.